This article and associated images are based on a poster originally authored by Denise Sullivan, Zhong Yu, Benjamin Streeter, Stacie Chvatal and Daniel Millard and presented at ELRIG Drug Discovery ...
Serplulimab achieves pharmacodynamic saturation, supporting its current clinical use without the need for higher doses. The ASTRUM-005 trial established serplulimab as the PD-1 inhibitor with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback